Karyopharm Therapeutics (KPTI) Reports Q4 Loss of $0.81/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Jefferies Remains Sidelined on Karyopharm Therapeutics (KPTI) Following 4Q - PT to $10
March 15, 2016 8:39 AM EDTJefferies reiterated a Hold rating on Karyopharm Therapeutics (NASDAQ: KPTI), and cut the price target to $10.00 (from $14.00), following the company's 4Q earnings report. Total operating expenses for 4Q were $29.3M consisting of $24.1M of R&D vs. a $24.5M estimate and... More
